Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Cellino
AddedFeb 15, 2024
UpdatedJul 17, 2026
Cellino

Cellino

Series A

Cellino: An AI-guided regenerative medicine firm innovating cell-based therapies and stem cell production.

HQ
Cambridge, MA, US
Founded
2017
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to revolutionize regenerative medicine, Cellino is dedicated to developing an AI-guided single-cell laser editing platform for cell-based therapies. The company focuses on automating and standardizing autologous stem cell production, aiming to accelerate the development of life-saving medical treatments. By leveraging cutting-edge technology, Cellino seeks to make personalized regenerative therapies more accessible and scalable, targeting a broad market within the healthcare industry.

Cellino has attracted notable investors and industry leaders, contributing to its rapid growth and innovation. The company's achievements include the successful development of a scalable platform that enhances the efficiency and precision of stem cell production. This breakthrough has significant implications for the future of personalized medicine, positioning Cellino as a key player in the field of regenerative therapies.

Cellino - Similar Companies

Cell BioEngines logo

Cell BioEngines

cellbioengines.com

Celularity logo

Celularity

celularity.com

Celvive logo

Celvive

RhinoCyte logo

RhinoCyte

rhinocyte.com

Cellebration Life Sciences logo

Cellebration Life Sciences

RoosterBio logo

RoosterBio

LaCell logo

LaCell

Personalized Stem Cells logo

Personalized Stem Cells

HebeCell logo

HebeCell

hebecellcorp.com

Stemedica Cell Technologies logo

Stemedica Cell Technologies

stemedica.com

Xcell Biosciences logo

Xcell Biosciences

xcellbio.com

Cellular Approaches logo

Cellular Approaches

Cellares logo

Cellares

cellares.com

Platelet BioGenesis logo

Platelet BioGenesis

Cellular Engineering Technologies logo

Cellular Engineering Technologies

celleng-tech.com

Cellino - Quick Facts

Who are Cellino's competitors?

Companies similar to Cellino include Cell BioEngines, Celularity, Celvive and RhinoCyte.

When was Cellino founded?

Cellino was founded in 2017.

Where is Cellino's headquarters located?

Cellino's headquarters is located in Cambridge, MA, US.

When was Cellino's last funding round?

Cellino's most recent funding round was for $80M (USD) in January 2022.

How much has Cellino raised to-date?

As of Jan 25, 2022, Cellino has raised a total of $97.5M (USD).

How many employees does Cellino have?

Cellino has 89 employees as of Feb 5, 2024.

Cellino - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • AI
  • Biotech
Geographic Exposure
  • Americas
Model
  • Platform
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Stem Cell Therapies
Tags
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified